TY - JOUR
T1 - Radiographic damage and progression of the cervical spine in ankylosing spondylitis patients treated with TNF-alpha inhibitors
T2 - Facet joints vs. vertebral bodies
AU - Maas, Fiona
AU - Spoorenberg, Anneke
AU - Brouwer, Elisabeth
AU - van der Veer, Eveline
AU - Bootsma, Hendrika
AU - Bos, Reinhard
AU - Wink, Freke R.
AU - Arends, Suzanne
N1 - Copyright © 2016 Elsevier Inc. All rights reserved.
PY - 2017/4
Y1 - 2017/4
N2 - Objectives: To investigate radiographic damage and 4-year progression of the cervical facet joints in a prospective observational cohort of AS patients treated with TNF-alpha inhibitors, to compare this with damage and progression of the cervical vertebral bodies, and to study the relation with patient characteristics and clinical outcome.Methods: Patients from the Groningen Leeuwarden AS (GLAS) cohort starting TNF-alpha inhibitors with baseline and 4-year radiographs were included. Cervical facet joints and vertebral bodies were scored by two independent readers according to the method of de Vlam and mSASSS, respectively.Results: At baseline, 25 of 99 (25%) AS patients had partial or complete ankylosis of the cervical facet joints, whereas 51 (52%) patients had non-bridging or bridging syndesmophytes of cervical vertebral bodies. During 4 years, 13 (13%) patients developed new (partial) ankylosis of the facet joints, whereas 26 (26%) developed new (bridging) syndesmophytes. Facet joint damage and progression without involvement of the vertebral bodies were seen in 5 (5%) and 8 (8%) patients, respectively. Damage of facet joints was associated with longer disease duration, history of IBD/uveitis/psoriasis, higher disease activity, larger occiput-to-wall distance, higher mSASSS, and presence of syndesmophytes. Progression of the facet joints was associated with larger occiput-to-wall distance and more facet joint damage at baseline.Conclusions: Cervical facet joints were frequently involved in AS. During 4 years of TNF-alpha blocking therapy, 13% of the patients showed radiographic progression of cervical facet joints of which the majority did not show progression of vertebral bodies. (C) 2017 Elsevier Inc. All rights reserved.
AB - Objectives: To investigate radiographic damage and 4-year progression of the cervical facet joints in a prospective observational cohort of AS patients treated with TNF-alpha inhibitors, to compare this with damage and progression of the cervical vertebral bodies, and to study the relation with patient characteristics and clinical outcome.Methods: Patients from the Groningen Leeuwarden AS (GLAS) cohort starting TNF-alpha inhibitors with baseline and 4-year radiographs were included. Cervical facet joints and vertebral bodies were scored by two independent readers according to the method of de Vlam and mSASSS, respectively.Results: At baseline, 25 of 99 (25%) AS patients had partial or complete ankylosis of the cervical facet joints, whereas 51 (52%) patients had non-bridging or bridging syndesmophytes of cervical vertebral bodies. During 4 years, 13 (13%) patients developed new (partial) ankylosis of the facet joints, whereas 26 (26%) developed new (bridging) syndesmophytes. Facet joint damage and progression without involvement of the vertebral bodies were seen in 5 (5%) and 8 (8%) patients, respectively. Damage of facet joints was associated with longer disease duration, history of IBD/uveitis/psoriasis, higher disease activity, larger occiput-to-wall distance, higher mSASSS, and presence of syndesmophytes. Progression of the facet joints was associated with larger occiput-to-wall distance and more facet joint damage at baseline.Conclusions: Cervical facet joints were frequently involved in AS. During 4 years of TNF-alpha blocking therapy, 13% of the patients showed radiographic progression of cervical facet joints of which the majority did not show progression of vertebral bodies. (C) 2017 Elsevier Inc. All rights reserved.
KW - Ankylosing spondylitis
KW - Zygapophyseal joint
KW - Radiographic progression
KW - Bone formation
KW - Tumor necrosis factor-alpha blocking therapy
KW - PSORIATIC-ARTHRITIS
KW - SCORING METHODS
KW - INVOLVEMENT
KW - SYNDESMOPHYTES
U2 - 10.1016/j.semarthrit.2016.11.003
DO - 10.1016/j.semarthrit.2016.11.003
M3 - Review article
C2 - 28040243
SN - 0049-0172
VL - 46
SP - 562
EP - 568
JO - SEMINARS IN ARTHRITIS AND RHEUMATISM
JF - SEMINARS IN ARTHRITIS AND RHEUMATISM
IS - 5
ER -